1423-61-6

Usage

Uses

Used in Pharmaceutical Industry:
7-Bromo-benzo[b]thiophene is used as a starting material for the synthesis of various bioactive compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs and materials.
Used in Organic Synthesis:
7-Bromo-benzo[b]thiophene is used as an intermediate in the preparation of functionalized benzothiophene derivatives. Its bromo group allows for further chemical modifications, making it a versatile building block in the synthesis of complex organic molecules.
Used in Agrochemical Industry:
7-Bromo-benzo[b]thiophene is also utilized in the development of agrochemicals, where its unique properties and reactivity contribute to the creation of effective and targeted compounds for agricultural applications.

InChI:InChI=1/C8H5BrS/c9-7-3-1-2-6-4-5-10-8(6)7/h1-5H

Upstream product

• 137105-52-3 2-(2-bromophenylthio) acetaldehyde diethyl acetal 
• 6320-02-1 o-bromothiophenol 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 149947-15-9 3-bromo-2-fluorobenzaldehyde 
• 550998-53-3 methyl 7-bromobenzo[b]thiophene-2-carboxylate 
• 19075-59-3 7-bromo-1-benzothiophene-2-carboxylic acid 
• 864684-51-5 (2-bromophenylthiomethyl)-1,3-dioxolane 
• 615-36-1 2-bromoaniline 
• 799766-06-6 1-bromo-2-((2,2-dimethoxyethyl)sulfanyl)benzene 

Downstream Products

• 22780-71-8 benzo[b]thiophene-7-carbonitrile 
• 874142-91-3 7-(2-formylphenyl)benzo[b]thiophene 
• 842167-37-7 7-(2-formyl-4-methoxyphenyl)benzo[b]thiophene 
• 842167-38-8 2-(2-benzo[b]thiophen-7-yl-5-methoxy-phenyl)-oxirane 
• 195-68-6 phenanthro[4,3-b]thiophene 
• 10134-98-2 benzothiophen-7-carboxic acid 
• 10134-91-5 benzo[b]thiophene-7-carboxaldehyde 
• 1037763-27-1 C₂₅H₁₉F₂N₃O₄S₂ 
• 1037758-60-3 C₂₄H₁₇F₂N₃O₄S₂ 
• 1037763-23-7 C₂₅H₁₈F₂N₂O₃S 
• 1037763-25-9 C₂₄H₁₆F₂N₂O₃S 
• 1037758-22-7 6-(2,5-difluorobenzyl)-8-(2-oxo-1,2-dihydropyridin-3-yl)-6H-thieno[2,3-e]indole-7-carboxylic acid 

Relevant academic research and scientific papers

Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules

STAT3 is an attractive therapeutic target for cancer therapy. However, due to low potency or poor druggability, none of its inhibitors are clinically available. Herein, a series of aminobenzo[b]thiophene 1, 1-dioxides with good drug-likeness properties were designed, synthesized and evaluated as STAT3 inhibitors. Most of them exhibited higher antitumor activity than the small-molecule STAT3 inhibitor, Stattic. Compound 15 was the most potent and had an IC50range in 0.33–0.75?μM in various cancer cell lines. The overexpressed and IL-6 induced phosphorylation levels of STAT3 were both inhibited by 15 without influencing the phosphorylation levels of the upstream kinases Src and Jak2. 15 also suppressed the expressions of STAT3 downstream gene, Bcl-2. 15 effectively increased the ROS levels of cancer cells, induced cancer cell apoptosis and abolished the colony formation ability of cancer cells without affecting bypass kinase p-Erk. Furthermore, 15 in?vivo induced significant antitumor responses, and exhibited less toxicity than Doxorubicin. Together, this study described a class of new STAT3 inhibitors as antitumor agents.

Lithiated benzothiophenes and benzofurans require 2-silyl protection to avoid anion migration

2-Trimethylsilyl protection of benzothiophenes and benzofurans prevents anion migration to the 2-position when lithiated species are formed. These lithiated benzothiophenes and benzofurans provide superior results in additions to piperidones. Deprotection is conveniently achieved under acidic conditions. Direct C-7 metalation of benzothiophene is enabled by 2-triisopropylsilyl protection at C-2.

Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists

N-Benzyl substitution of phenethylamine 5-HT2A receptor agonists has dramatic effects on binding affinity, receptor selectivity and agonist activity. In this paper we examine how affinity for the 5-HT2A/2C receptors are influenced by N-benzyl substitution of 4-bromo-2,5-dimethoxyphenethylamine derivatives. Special attention is given to the 2′ and 3′-position of the N-benzyl as such compounds are known to be very potent. We found that substitutions in these positions are generally well tolerated. The 2′-position was further examined using a range of substituents to probe the hydrogen bonding requirements for optimal affinity and selectivity, and it was found that small changes in the ligands in this area had a profound effect on their affinities. Furthermore, two ligands that lack a 2′-benzyl substituent were also found to have high affinity contradicting previous held notions. Several high-affinity ligands were identified and assayed for functional activity at the 5-HT2A and 5-HT2C receptor, and they were generally found to be less efficacious agonists than previously reported N-benzyl phenethylamines.

INHIBITORS OF THE KYNURENINE PATHWAY

The present application provides novel inhibitors of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase, metabolites thereof, and phannaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. A therapeutically effective amount of one or more of the compounds of formula (I) is useful in treating diseases resulting from dysregulation of the kynurenine pathway. Compounds of formula (I) act by inhibiting the enzymatic activity or expression of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase.

OLIGOMERISATION OF ETHYLENE TO MIXTURES OF 1-HEXENE AND 1-OCTENE

A process for the otigomerisation of ethylene to predominantly 1-hexene or 1-octene or mixtures of 1-hexene and 1-octene includes contacting ethylene with a catalyst under ethylene oligomerisation conditions. The catalyst comprises a source of chromium, a diphosphine ligating compound, and optionally an activator. The diphosphine ligating compound includes at least one optionally substituted fused cyclic structure including at least two rings, the optionally substituted fused cyclic structure including a 5- to 7- membered aromatic first ring bonded to a phosphorus atom, the aromatic first ring being fused to a 4- to 8-membered heterocyclic second ring, the heterocyclic second ring including a heteroatom which is separated by two ring atoms along the shortest connecting path from the phosphorous atom that is bonded to the first aromatic ring.

BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES

Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following (formula I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

FUSED HETEROCYCLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF

The present invention provides nitrogen-containing fused cyclic derivatives represented by the following general formula or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula one of R1 and R4 represents a group represented by the following general formula (S) (in which R5 and R6 represent H, OH, a halogen atom, etc.; Q represents an alkylene group etc.; and ring A represents an aryl group etc.), and the other represents H, OH, an amino group, etc.; R2 and R3 represent H, OH, an amino group, a halogen atom, and an optionally substituted alkyl group, etc.; A1 represents O, S, etc.; A2 represents CH or N; G represents a group represented by the following general formula (G-1) or (G-2) (E1 represents H, F or OH; and E2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS

This invention provides estrogen receptor modulators having the structure (I) where R1-R5 are as defined in the specification; or a pharmaceutically acceptable salt thereof.

Piperidine derivatives having effects on serotonin related systems

The present invention provides the compounds of the following formula: Wherein the variables are as defined in the specification and a method for inhibiting the reuptake of seretonin, antagonizing the 5-HT1Areceptor and antagonizing the 5-HT2Areceptor which comprises administering to a subject in need of such treatment an effective amount of the compound of above formula.